Detail akcie Ardelyx online

Business Summary: Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Ardelyx Inc revenues increased 30% to $282.1M. Net loss increased 40% to $61.2M. Revenues reflect IBSRELA segment increase of 72% to $109.4M, Research and development of biopharmaceutical products. segment increase of 12% to $110.3M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.19 to -$0.26.